Abstract

Hatice AKAY,MD, Nilgül AKALIN,MD, �?zlem HARMANKAYA, MD, Doç. , Mehmet Köro�?lu,MD, Baki Kumbasar, MD, Doç.

In this study, we compared anemia and bone metabolism in patients undergone hemodialysis and peritoneal dialysis replacement therapy. We aimed to demonstrate superiority of the replacement therapies in terms of anemia and bone metabolism. The levels of serum iron, iron binding capacity, ferritin, hemogram, calcium, phosphorus and parathormone were measured in the patients. In all patients were recorded ıron, erythropoiesis stimulation therapy, phosphorus lowering medications containing calcium and active vitamin D therapy and the mean therapy doses were calculated. No differences were found in the distribution of mean age and gender and mean duration of dialysis between the groups. Mean hemoglobine and mean hematocrit values of the dialysis groups were found to be similar. Hemodialysis patient group was observed to receive erythropoiesis stimulation therapy in higher doses than the peritoneal dialysis patient group. There was not significant difference between both the groups in terms of phosphorus binding therapy and active vitamin D therapy. No significant difference was observed between the dialysis groups in terms of anemia and bone metabolism.